Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Abraham S, Juel HB, Bang P, Cheeseman HM, Dohn RB, Cole T, Kristiansen MP, Korsholm KS, Lewis D, Olsen AW, McFarlane LR, Day S, Knudsen S, Moen K, Ruhwald M, Kromann I, Andersen P, Shattock RJ, Follmann F.

Lancet Infect Dis. 2019 Aug 12. pii: S1473-3099(19)30279-8. doi: 10.1016/S1473-3099(19)30279-8. [Epub ahead of print]

PMID:
31416692
2.

KLRG1-Expressing CD4 T Cells Are Reduced in Tuberculosis Patients Compared to Healthy Mycobacterium tuberculosis-Infected Subjects, but Increase With Treatment.

Tonby K, Mortensen R, Ruhwald M, Dyrhol-Riise AM, Jenum S.

J Infect Dis. 2019 Jun 5;220(1):174-176. doi: 10.1093/infdis/jiz056. No abstract available.

PMID:
30888024
3.

Use of IP-10 detection in dried plasma spots for latent tuberculosis infection diagnosis in contacts via mail.

Villar-Hernández R, Latorre I, De Souza-Galvão ML, Jiménez MA, Ruiz-Manzano J, Pilarte J, García-García E, Muriel-Moreno B, Cantos A, Altet N, Millet JP, González-Díaz Y, Molina-Pinargote I, Prat C, Ruhwald M, Domínguez J.

Sci Rep. 2019 Mar 8;9(1):3943. doi: 10.1038/s41598-019-40778-1.

4.

IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting.

Hoel IM, Jørstad MD, Marijani M, Ruhwald M, Mustafa T, Dyrhol-Riise AM.

Sci Rep. 2019 Mar 7;9(1):3871. doi: 10.1038/s41598-019-40458-0.

5.

Diagnostic accuracy of ESAT-6 free IGRA compared to QuantiFERON-TB Gold In-tube.

Nemes E, Abrahams D, Scriba TJ, Ratangee F, Keyser A, Makhethe L, Erasmus M, Mabwe S, Bilek N, Rozot V, Geldenhuys H, Hatherill M, Lempicki MD, Holm LL, Bogardus L, Ginsberg AM, Blauenfeldt T, Smith B, Ellis RD, Loxton AG, Walzl G, Andersen P, Ruhwald M.

Clin Infect Dis. 2019 Jan 21. doi: 10.1093/cid/ciz034. [Epub ahead of print]

PMID:
30668657
6.

Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial.

Aggerbeck H, Ruhwald M, Hoff ST, Tingskov PN, Hellstrom E, Malahleha M, Siebert M, Gani M, Diacon A, Novelijc Z, Andersen P, Dheda K.

Int J Tuberc Lung Dis. 2019 Jan 1;23(1):38-44. doi: 10.5588/ijtld.18.0137. Epub 2018 Dec 20.

PMID:
30572979
7.

Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis.

Ruhwald M, Diel R.

Eur Respir J. 2018 Oct 25;52(4). pii: 1801616. doi: 10.1183/13993003.01616-2018. Print 2018 Oct. No abstract available.

PMID:
30361266
8.

C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial.

Aggerbeck H, Ruhwald M, Hoff ST, Borregaard B, Hellstrom E, Malahleha M, Siebert M, Gani M, Seopela V, Diacon A, Lourens M, Andersen P, Dheda K.

PLoS One. 2018 Sep 24;13(9):e0204554. doi: 10.1371/journal.pone.0204554. eCollection 2018.

9.

First description of agonist and antagonist IP-10 in urine of patients with active TB.

Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, Delogu G, Ciccosanti F, Fimia GM, Blauenfeldt T, Ruhwald M, Duffy D, Goletti D.

Int J Infect Dis. 2019 Jan;78:15-21. doi: 10.1016/j.ijid.2018.09.001. Epub 2018 Sep 7.

10.

Boosting effect of IL-7 in interferon gamma release assays to diagnose Mycobacterium tuberculosis infection.

Hiza H, Fenner L, Hella J, Kuchaka D, Sasamalo M, Blauenfeldt T, Kibiki G, Kavishe RA, Mhimbira F, Ruhwald M.

PLoS One. 2018 Aug 29;13(8):e0202525. doi: 10.1371/journal.pone.0202525. eCollection 2018.

11.

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo.

Holm LL, Vukmanovic-Stejic M, Blauenfeldt T, Benfield T, Andersen P, Akbar AN, Ruhwald M.

J Vis Exp. 2018 Aug 11;(138). doi: 10.3791/57554.

12.

Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.

Suliman S, Luabeya AKK, Geldenhuys H, Tameris M, Hoff ST, Shi Z, Tait D, Kromann I, Ruhwald M, Rutkowski KT, Shepherd B, Hokey D, Ginsberg AM, Hanekom WA, Andersen P, Scriba TJ, Hatherill M; H56-035 Trial Group.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231. doi: 10.1164/rccm.201802-0366OC.

PMID:
30092143
13.

Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis.

Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE.

Clin Microbiol Infect. 2019 Feb;25(2):169-177. doi: 10.1016/j.cmi.2018.07.017. Epub 2018 Aug 2.

14.

Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.

Neesgaard B, Ruhwald M, Krarup HB, Weis N.

PLoS One. 2018 Jul 31;13(7):e0201629. doi: 10.1371/journal.pone.0201629. eCollection 2018.

15.

Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions.

Blauenfeldt T, Petrone L, Del Nonno F, Baiocchini A, Falasca L, Chiacchio T, Bondet V, Vanini V, Palmieri F, Galluccio G, Casrouge A, Eugen-Olsen J, Albert ML, Goletti D, Duffy D, Ruhwald M.

Front Immunol. 2018 Jul 5;9:1456. doi: 10.3389/fimmu.2018.01456. eCollection 2018.

16.

Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial.

Nissen TN, Birk NM, Blok BA, Arts RJW, Andersen A, Kjærgaard J, Thøstesen LM, Hoffmann T, Jeppesen DL, Nielsen SD, Kofoed PE, Stensballe LG, Aaby P, Ruhwald M, Netea MG, Benn CS, Pryds O.

Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):29-41. doi: 10.1007/s10096-017-3097-2. Epub 2017 Sep 10.

PMID:
28890996
17.

Use of IFN-γ and IP-10 detection in the diagnosis of latent tuberculosis infection in patients with inflammatory rheumatic diseases.

Villar-Hernández R, Latorre I, Mínguez S, Díaz J, García-García E, Muriel-Moreno B, Lacoma A, Prat C, Olivé A, Ruhwald M, Mateo L, Domínguez J.

J Infect. 2017 Oct;75(4):315-325. doi: 10.1016/j.jinf.2017.07.004. Epub 2017 Jul 25.

PMID:
28751171
18.

Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Nemes E, Rozot V, Geldenhuys H, Bilek N, Mabwe S, Abrahams D, Makhethe L, Erasmus M, Keyser A, Toefy A, Cloete Y, Ratangee F, Blauenfeldt T, Ruhwald M, Walzl G, Smith B, Loxton AG, Hanekom WA, Andrews JR, Lempicki MD, Ellis R, Ginsberg AM, Hatherill M, Scriba TJ; C-040-404 Study Team and the Adolescent Cohort Study Team.

Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648. doi: 10.1164/rccm.201704-0817OC.

19.

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.

Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, Geldenhuys H, Smit E, Abrahams D, Rozot V, Dintwe O, Hoff ST, Kromann I, Ruhwald M, Bang P, Larson RP, Shafiani S, Ma S, Sherman DR, Sette A, Lindestam Arlehamn CS, McKinney DM, Maecker H, Hanekom WA, Hatherill M, Andersen P, Scriba TJ, Urdahl KB.

Cell Host Microbe. 2017 Jun 14;21(6):695-706.e5. doi: 10.1016/j.chom.2017.05.012.

20.

Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.

Neesgaard B, Ruhwald M, Weis N.

World J Hepatol. 2017 May 18;9(14):677-688. doi: 10.4254/wjh.v9.i14.677. Review.

21.

Optimisation of a murine splenocyte mycobacterial growth inhibition assay using virulent Mycobacterium tuberculosis.

Jensen C, Lindebo Holm L, Svensson E, Aagaard C, Ruhwald M.

Sci Rep. 2017 Jun 6;7(1):2830. doi: 10.1038/s41598-017-02116-1.

22.

Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6.

Ruhwald M, de Thurah L, Kuchaka D, Zaher MR, Salman AM, Abdel-Ghaffar AR, Shoukry FA, Michelsen SW, Soborg B, Blauenfeldt T, Mpagama S, Hoff ST, Agger EM, Rosenkrands I, Aagard C, Kibiki G, El-Sheikh N, Andersen P.

Sci Rep. 2017 Apr 7;7:45969. doi: 10.1038/srep45969.

23.

Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial.

Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B, Martinez JA, Kromann I, Penas A, Anibarro LL, de Souza-Galvão ML, Sánchez F, Rodrigo-Pendás JÁ, Noguera-Julian A, Martínez-Lacasa X, Tuñez MV, Fernández VL, Millet JP, Moreno A, Cobos N, Miró JM, Roldan L, Orcau A, Andersen P, Caylá JA; TESEC Working Group.

Lancet Respir Med. 2017 Apr;5(4):259-268. doi: 10.1016/S2213-2600(16)30436-2. Epub 2017 Feb 1.

PMID:
28159608
24.

H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.

Mearns H, Geldenhuys HD, Kagina BM, Musvosvi M, Little F, Ratangee F, Mahomed H, Hanekom WA, Hoff ST, Ruhwald M, Kromann I, Bang P, Hatherill M, Andersen P, Scriba TJ; THYB04 study group.

Vaccine. 2017 Jan 3;35(1):132-141. doi: 10.1016/j.vaccine.2016.11.023. Epub 2016 Nov 18.

PMID:
27866772
25.

New tests for detection of Mycobacterium tuberculosis infection: sufficient to meet the WHO 2035 targets?

Ruhwald M, Andersen PL.

Future Microbiol. 2016 Sep;11:1101-4. doi: 10.2217/fmb-2016-0131. Epub 2016 Aug 22. No abstract available.

26.

TB vaccines in clinical development.

Ginsberg AM, Ruhwald M, Mearns H, McShane H.

Tuberculosis (Edinb). 2016 Aug;99 Suppl 1:S16-20. doi: 10.1016/j.tube.2016.05.013. Epub 2016 Jun 16.

PMID:
27470538
27.

TB biomarkers, TB correlates and human challenge models: New tools for improving assessment of new TB vaccines.

Kaufmann SH, Fortune S, Pepponi I, Ruhwald M, Schrager LK, Ottenhoff TH.

Tuberculosis (Edinb). 2016 Aug;99 Suppl 1:S8-S11. doi: 10.1016/j.tube.2016.05.010. Epub 2016 Jun 16.

28.

Thermostability of IFN-γ and IP-10 release assays for latent infection with Mycobacterium tuberculosis: A TBnet study.

Blauenfeldt T, Wagner D, Aabye M, Heyckendorf J, Lange B, Lange C, Ernst M, Ravn P, Duarte R, Morais C, Hoffmann M, Schoch OD, Dominguez J, Latorre I, Ruhwald M.

Tuberculosis (Edinb). 2016 May;98:7-12. doi: 10.1016/j.tube.2015.04.013. Epub 2015 May 15.

PMID:
27156612
29.

Design of tuberculosis vaccine trials under financial constraints.

García-Basteiro AL, Ruhwald M, Lange C.

Expert Rev Vaccines. 2016 Jul;15(7):799-801. doi: 10.1080/14760584.2016.1178067. Epub 2016 May 9. No abstract available.

PMID:
27078056
30.

Performance of Interferon-Gamma and IP-10 Release Assays for Diagnosing Latent Tuberculosis Infections in Patients with Concurrent Malaria in Tanzania.

Drabe CH, Vestergaard LS, Helleberg M, Nyagonde N, Rose MV, Francis F, Theilgaard OP, Asbjørn J, Amos B, Bygbjerg IC, Ruhwald M, Ravn P.

Am J Trop Med Hyg. 2016 Apr;94(4):728-35. doi: 10.4269/ajtmh.15-0633. Epub 2016 Feb 1.

31.

Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection.

Hoff ST, Peter JG, Theron G, Pascoe M, Tingskov PN, Aggerbeck H, Kolbus D, Ruhwald M, Andersen P, Dheda K.

Eur Respir J. 2016 Mar;47(3):919-28. doi: 10.1183/13993003.01464-2015. Epub 2015 Dec 17.

32.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

33.

IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection.

Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM.

Sci Rep. 2015 Mar 18;5:9223. doi: 10.1038/srep09223.

34.

Human B cells produce chemokine CXCL10 in the presence of Mycobacterium tuberculosis specific T cells.

Hoff ST, Salman AM, Ruhwald M, Ravn P, Brock I, Elsheikh N, Andersen P, Agger EM.

Tuberculosis (Edinb). 2015 Jan;95(1):40-7. doi: 10.1016/j.tube.2014.10.005. Epub 2014 Oct 22.

PMID:
25476870
35.

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.

van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, O'Dee DM, Graves A, Thierry-Carstensen B, Andreasen LV, Ruhwald M, de Visser AW, Agger EM, Ottenhoff TH, Kromann I, Andersen P.

Vaccine. 2014 Dec 12;32(52):7098-107. doi: 10.1016/j.vaccine.2014.10.036. Epub 2014 Oct 30.

36.

A comparison of interferon-γ and IP-10 for the diagnosis of tuberculosis.

Holm LL, Rose MV, Kimaro G, Bygbjerg IC, Mfinanga SG, Ravn P, Ruhwald M.

Pediatrics. 2014 Dec;134(6):e1568-75. doi: 10.1542/peds.2014-1570.

37.

Development of a one-step probe based molecular assay for rapid immunodiagnosis of infection with M. tuberculosis using dried blood spots.

Blauenfeldt T, Heyckendorf J, Graff Jensen S, Lange C, Drabe C, Hermansen TS, de Thurah L, Lillebaek T, Eugen-Olsen J, Seersholm N, Hoff S, Bonde J, Ruhwald M.

PLoS One. 2014 Sep 3;9(9):e105628. doi: 10.1371/journal.pone.0105628. eCollection 2014.

38.

IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children.

Latorre I, Díaz J, Mialdea I, Serra-Vidal M, Altet N, Prat C, Díez N, Escribano A, Casas I, Rodrigo C, Ausina V, Ruhwald M, Domínguez J.

J Infect. 2014 Dec;69(6):590-9. doi: 10.1016/j.jinf.2014.06.013. Epub 2014 Jun 27.

PMID:
24975172
39.

Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.

Heyckendorf J, Olaru ID, Ruhwald M, Lange C.

Am J Respir Crit Care Med. 2014 Aug 15;190(4):374-83. doi: 10.1164/rccm.201402-0363PP. Review.

PMID:
24941306
40.

ELISA-based assay for IP-10 detection from filter paper samples.

Drabe CH, Blauenfeldt T, Ruhwald M.

Methods Mol Biol. 2014;1172:27-37. doi: 10.1007/978-1-4939-0928-5_3.

PMID:
24908292
41.

6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark.

Soborg C, Ruhwald M, Andersen PH, Ravn P.

Eur Respir J. 2014 Aug;44(2):540-3. doi: 10.1183/09031936.00170913. Epub 2014 May 2. No abstract available.

42.

Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis.

Chegou NN, Heyckendorf J, Walzl G, Lange C, Ruhwald M.

Eur Respir J. 2014 May;43(5):1472-86. doi: 10.1183/09031936.00151413. Epub 2013 Dec 5. Review.

43.

Inflammatory markers in the second trimester prior to clinical onset of preeclampsia, intrauterine growth restriction, and spontaneous preterm birth.

Haedersdal S, Salvig JD, Aabye M, Thorball CW, Ruhwald M, Ladelund S, Eugen-Olsen J, Secher NJ.

Inflammation. 2013 Aug;36(4):907-13. doi: 10.1007/s10753-013-9619-x.

PMID:
23471783
44.

Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper.

Aabye MG, Latorre I, Diaz J, Maldonado J, Mialdea I, Eugen-Olsen J, Ravn P, Dominguez J, Ruhwald M.

Eur Respir J. 2013 Aug;42(2):495-503. doi: 10.1183/09031936.00129412. Epub 2013 Jan 24.

45.

Negative effect of smoking on the performance of the QuantiFERON TB gold in tube test.

Aabye MG, Hermansen TS, Ruhwald M, Praygod G, Faurholt-Jepsen D, Jeremiah K, Faurholt-Jepsen M, Range N, Friis H, Changalucha J, Andersen AB, Ravn P.

BMC Infect Dis. 2012 Dec 27;12:379. doi: 10.1186/1471-2334-12-379.

46.

Evaluation of the filter paper IP-10 tests in school children after exposure to tuberculosis: a prospective cohort study with a 4-year follow-up.

Tuuminen T, Salo E, Kotilainen H, Ruhwald M.

BMJ Open. 2012 Dec 4;2(6). pii: e001751. doi: 10.1136/bmjopen-2012-001751. Print 2012.

47.

Point-of-care diagnosis of tuberculosis: past, present and future.

Dheda K, Ruhwald M, Theron G, Peter J, Yam WC.

Respirology. 2013 Feb;18(2):217-32. doi: 10.1111/resp.12022. Review.

48.

IP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection.

Ruhwald M, Andersen ES, Christensen PB, Moessner BK, Weis N.

PLoS One. 2012;7(9):e45181. Epub 2012 Sep 14.

49.

A simple method to quantitate IP-10 in dried blood and plasma spots.

Aabye MG, Eugen-Olsen J, Werlinrud AM, Holm LL, Tuuminen T, Ravn P, Ruhwald M.

PLoS One. 2012;7(6):e39228. doi: 10.1371/journal.pone.0039228. Epub 2012 Jun 27.

50.

IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions.

Ruhwald M, Aabye MG, Ravn P.

Expert Rev Mol Diagn. 2012 Mar;12(2):175-87. doi: 10.1586/erm.11.97. Review.

PMID:
22369377

Supplemental Content

Loading ...
Support Center